Premenopausal node-negative breast cancer: May adjuvant chemotherapy be indicated by the analysis of nuclear DNA dynamics?

Breast Cancer Research and Treatment

Volumn 42, Issue 3, 1997, Pages 253-263

  Wyss Desserich, Marie Thérèse ^a   Caduff Joos, Rosmarie ^a   Wyss, Pius ^a   Rageth, Christoph ^b   Wight, Edward ^a   Unger, Christian ^a   Walt, Heinrich ^a   Haller, Urs ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Limmattal Hospital   (Switzerland)

Author keywords

Breast cancer; DNA flow cytometry; Histological grade; Hormonal receptors; Premenopausal node negative; Prognosis; S+(G2+M) phase fraction

Indexed keywords

BIOCHEMICAL MARKER; CELL MARKER; ESTROGEN RECEPTOR; PARAFFIN; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; DNA DETERMINATION; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLOIDY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT PLANNING; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CELL CYCLE; CELL NUCLEUS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPH NODES; MULTIVARIATE ANALYSIS; PLOIDIES; PREMENOPAUSE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0031041031     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005729304068     Document Type: Article

References (40)

1. NCI alert on node-negative breast cancer (editorial). Breast Cancer Res Treat 12: 3-5, 1988
2. Fisher B, Radvin RG, Ausman RK, Slack NH, Moore GE, Noer RJ: Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 168: 337-356, 1968
3. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627-633, 1989
4. Yuan J, Hennessy C, Corbett IP, Dykin R, Givan AL, Shenton BK, Henry JA, Wright C, Lennard TWJ: Node negative breast cancer: the prognostic value of DNA ploidy for long-term survival. Br J Surg 78: 844-848, 1991
5. Blaslev I, Christensen I, Bruun Rasmussen B, Larsen J, Lykkesfeldt A, Thorpe S, Rose C, Briand P, Mouridsen H: Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer. Int J Cancer 56: 16-25, 1994
6. Keyhani-Rofagha S, O'Toole R, Farrar WB, Sickle-Santanello B, DeCenzo J, Young D: Is DNA ploidy an independent prognostic indicator in infiltrative node-negative breast adenocarcinoma? Cancer 65: 1577-1582, 1990
7. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957
8. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA: Method for analysis of cellular DNA content on paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31: 1333-1335, 1983
9. Jacobsen AB, Fossa SD, Thorud E, Lunde S, Melvik JE, Pettersen EO: DNA flow cytometric values in bladder carcinoma biopsies obtained from fresh and paraffin-embedded material. APMIS 96: 25-29, 1988
10. Heiden T, Wang N, Tribukait B: An improved Hedley method for preparation of paraffin-embedded tissues for flow cytometric analysis of ploidy and S-phase. Cytometry 12: 614-621, 1991
11. Dressler LG, Gray ER, Tormey DC, McGuire WL, Gilchrist KW, Clark GM, Osborne CK, Mansour EG, Abeloff MD: Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076). Monogr Natl Cancer Inst 11: 167-172, 1992
12. Muss HB, Kute TE, Case LD, Smith LR, Booher C, Long R, Kammire L, Gregory B, Brockschmidt JK: The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer 64: 1894-1900, 1989
13. Thorpe SM: Steroid receptors in breast cancer. Sources of interlaboratory variation in dextran-charcoal assays. Breast Cancer Res Treat 9: 175-189, 1987
14. Roth J, Saremaslani P, Warhol MJ: Improved accuracy in diagnostic immunohistochemistry, lectin immunohistochemistry and in situ hybridisation using a gold-labeled horse-radish peroxidase antibody and silver intensification. Lab Invest 67: 263-269, 1992
15. Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5: 95-115, 1985
16. Tancini G, Bonadonna CS, Valagussa P, Marchini S, Veronesi U: Adjuvant CMF in breast cancer: comparative 5 year results of 12 versus 6 cycles. J Clin Oncol 1: 2-10, 1983 (Abstr)
17. National Cancer Institute: The treatment of primary breast cancer: management of local disease. NIH Consensus Development Conference Summary 2: 29-30, 1979
18. Lykkesfeldt AE, Balslev I, Christensen IJ, Larsen JK, Molgaard H, Rasmussen BB, Thorpe S, Rose C: DNA ploidy and S-phase fraction in primary breast carcinomas in relation to prognostic factors and survival for premenopausal patients at high risk for recurrent disease. Acta Oncol 27: 749-756, 1988
19. Toikkanen S, Joensuu H, Klemi P: The prognostic significance of nuclear DNA content in invasive breast cancer - a study with long-term follow up. Br J Cancer 60: 693-700, 1989
20. Hedley DW, Rugg CA, Gelber RD: Association of DNA Index and S-phase fraction with prognosis of node positive early breast cancer. Cancer Res 47: 4729-4735, 1987
21. Lewis WE: Prognostic significance of flow cytometric DNA analysis in node-negative breast cancer patients. Cancer 65: 2315-2320, 1990
22. Winter K, Eidtmann H, Jonat W: Durchflusszytometrisch ermittelte S-Phasen-Fraktion und Ploidie als Prognoseparameter beim primären, nodal negativen Mammakarzinom. Geburtsh u Frauenheilk 54: 291-294, 1994
23. Winchester DJ, Duda RB, August CZ, Goldschmidt RA, Wruck DM, Rademaker AW, Winchester DP, Merkel DE: The importance of DNA flow cytometry in node-negative breast cancer. Arch Surg 125: 886-889, 1990
24. Hatschek T, Fagerberg G, Stal O, Sullivan S, Carstensen J, Gröntoft O, Nordenskjöld B: Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program. Cancer 64: 1074-1081, 1989
25. Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Fernö M, Killander D, Olsson H: Indicators of prognosis in node-negative breast cancer. N Engl J Med 322: 1045-1053, 1990
26. Stal O, Wingren S, Carstensen J, Rutqvist LE, Skoog L, Klintenberg C, Nordenskjold B: Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. Eur J Cancer Clin Oncol 25: 301-309, 1989
27. Fossa SD, Berner A, Waehre H, Heiden Holm Juul ME, van den Ouden D, Pettersen EO, Wang N, Tribukait B: DNA-ploidy in cell nuclei from paraffin-embedded material-comparison of results from two laboratories. Cytometry 13: 395-403, 1992
28. Kallioniemi OP, Joensuu H, Klemi P, Koivula T: Inter-laboratory comparison of DNA flow cytometric results from paraffin-embedded breast carcinoma. Breast Cancer Res Treat 17: 59-61, 1990
29. Kinne DW, Ashikari R, Butler A, Menendez-Botet C, Rosen PP, Schwartz M: Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer 47: 2364-2367, 1981
30. Moot SK, Peters GN, Cheek JH: Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma. Cancer 60: 382-385, 1987
31. Tsangaris TN, Knox SM, Cheek JH: Tumor hormone receptor status and recurrences in premenopausal patients with node-negative breast carcinoma. Cancer 69: 984-987, 1992
32. Butler JA, Bretsky S, Menendez-Botet C: Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer 55: 1178-1181, 1985
33. Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D, Rouessé J: The importance of histologie grade in long-term prognosis of breast cancer: a study of 1'010 patients, uniformly treated at the Institut Gustave Roussy. J Clin Oncol 5: 1378-1386, 1987
34. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, Golouh R, Save Soderbergh J, Holloway L, Russell I, Rudenstam CM: Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer wild axillary lymph node metastasis. Cancer 58: 2662-2670, 1986
35. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M: Prognostic value of histologie grade nuclear components of Scarff-Bloom-Richardson (SBR). A improved score modification based on a multivariate analysis of 1762 invasive ductal breast carcinoma. Cancer 64: 1914-1921, 1989
36. Stenkvist B, Bengtsson E, Eriksson O, Jarkans T, Nordin B, Westman Naeser S: Histo-pathological systems of breast cancer classification. Reproducibility and clinical significance. J Clin Pathol 36: 392-398, 1983
37. Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbriglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J, Roth JA: Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study. Breast Cancer Res Treat 5: 3-10, 1985
38. Jacquemier J, Vague D, Lieutaud R: Définition et reproductibilité du grading de Scarff et Bloom. In: Evaluation des mouens de diagnostic du cancer du sein. IIIe Journées de la Société Française du Sénologie et de Pathologie Mammaire. JMT Conseil, Versailles, 1981, pp 173-1851
39. Meyer JS, Koehm SL, Hughes JM, Higa E, Wittliff JL, Lagos JA, Manes JL: Bromodeoxyuridine labeling for S-phase measurement in breast carcinoma. Cancer 71(11): 3531-3540, 1993
40. Kubbutat MHG, Cattoretti G, Gerdes J, Key G: Comparison of monoclonal antibodies PC10 and MIB 1 on microwave-processed paraffin sections. Cell Prolif 27: 553-559, 1994